Published in Nat Med on September 14, 2014
A Study of ARRY-371797 in Patients With Rheumatoid Arthritis | NCT00729209
A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee | NCT01366014
High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet (2015) 2.35
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget (2016) 0.88
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol (2015) 0.86
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr) (2015) 0.84
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84
Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions. Cell Death Differ (2016) 0.83
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer (2015) 0.80
Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14. Hepatology (2015) 0.80
Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Proc Natl Acad Sci U S A (2015) 0.79
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene (2015) 0.79
Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget (2016) 0.79
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway. Oncotarget (2016) 0.78
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Sci Rep (2016) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature (2017) 0.77
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget (2015) 0.77
Liver cancer: sorafenib resistance uncovered by novel RNAi screen. Nat Rev Clin Oncol (2014) 0.77
p21 shapes cancer evolution. Nat Cell Biol (2016) 0.77
Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol (2015) 0.76
Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease. BMC Cancer (2015) 0.76
In vivo RNAi screens: concepts and applications. Trends Immunol (2015) 0.75
Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small (2015) 0.75
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. PLoS One (2015) 0.75
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. Front Cell Dev Biol (2016) 0.75
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. Oncotarget (2016) 0.75
Alpha fetoprotein antagonises benzyl isothiocyanate inhibition of the malignant behaviors of hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Targeting of non-oncogene addiction. Aging (Albany NY) (2015) 0.75
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep (2017) 0.75
MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma". Hepatobiliary Surg Nutr (2016) 0.75
Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells. Oncotarget (2017) 0.75
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of both Sorafenib Sensitive and Resistant HCC Cells by Inhibiting ATP Production. Gene Expr (2016) 0.75
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol (2005) 5.60
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc (2008) 4.02
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 3.89
p38 MAP kinases: beyond the stress response. Trends Biochem Sci (2000) 3.20
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95
Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 2.76
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax (2013) 1.77
A pipeline for the generation of shRNA transgenic mice. Nat Protoc (2012) 1.76
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci (2002) 1.53
p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel (2005) 1.43
Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci (2007) 1.38
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem (2010) 1.23
Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J (2006) 1.21
Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2008) 1.11
Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol (2011) 1.05
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut (2013) 1.04
Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther (2009) 0.92
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract (2011) 0.91
Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. J Med Chem (2012) 0.85
Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem (2007) 0.82
p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. Gut (2013) 1.49
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med (2016) 1.47
Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization. J Am Coll Cardiol (2015) 1.46
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood (2014) 1.09
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol (2013) 1.06
Semiconductor-based sequencing of formalin-fixed, paraffin-embedded colorectal cancer samples. Oncologist (2015) 0.89
A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett (2015) 0.84
Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol (2015) 0.81
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget (2015) 0.81
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev (2015) 0.81
PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. Hepatology (2016) 0.80
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathol Res Pract (2013) 0.78
Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. Mod Pathol (2014) 0.78
Induction of Chromosome Instability by Activation of Yes Associated Protein and Forkhead box M1 in Liver Cancer. Gastroenterology (2017) 0.77
MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget (2016) 0.77
General aspects and pitfalls in liver transplant pathology. Clin Transplant (2006) 0.77
Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. Am J Pathol (2016) 0.77
Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol (2014) 0.77
The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. J Hepatol (2017) 0.77
Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget (2016) 0.76
Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget (2016) 0.75
Cellular apoptosis susceptibility (CAS) is linked to integrin β1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget (2016) 0.75
MEK1 is required for the development of NRAS-driven leukemia. Oncotarget (2016) 0.75
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. J Clin Endocrinol Metab (2019) 0.75
Differences in virulence repertoire and cell invasive potential of group A Streptococcus emm1-2 in comparison to emm1 genotype. Int J Med Microbiol (2014) 0.75
Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury. Cardiovasc Res (2019) 0.75
A Field Guide for Cancer Diagnostics using cell-free DNA: From Principles to Practice and Clinical Applications. Genes Chromosomes Cancer (2017) 0.75
Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget (2017) 0.75
Limited role of interferon-kappa (IFNK) truncating mutations in common variable immunodeficiency. Cytokine (2017) 0.75
De novo synthesis of C4.4A in hepatocellular carcinoma promotes migration and invasion of tumor cells. Oncol Rep (2017) 0.75
Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study. Hepatology (2016) 0.75
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol (2017) 0.75
Proteomics in pathology. Proteomics (2017) 0.75
Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype. Int J Cancer (2021) 0.75